Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units (Canadian Version)

Montreal, QC – January 11, 2021 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf …Lire la suite

Theratechnologies To Present At The B. Riley Securities Virtual Oncology Investor Conference

Montreal, Canada – January 14, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology …Lire la suite

Theratechnologies Announces US$40 Million Bought-Deal Public Offering Of Units

Montreal, QC – January 11, 2021 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an agreement with a syndicate of Canadian underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters …Lire la suite

Theratechnologies Announces Preliminary Fourth Quarter And Full Fiscal Year 2020 Revenues And Provides Update On R&D Activities

Expects record Q4 and FY 2020 revenues  Receives ‘Study May Proceed’ letters from FDA for Phase 3 trial of tesamorelin in NASH and Phase 1 trial of TH1902 in various cancers  Montreal, Canada – January 7, 2021 – Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and …Lire la suite

Theratechnologies Announces New Findings For Its Lead Investigational Compound TH1902 For The Treatment Of Several Additional Cancers

In addition to ovarian and triple-negative breast cancers, TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers IND-enabling toxicity study concludes that TH1902 can be administered at 3 times the maximum tolerated dose of docetaxel alone Significant potential to improve therapeutic window    Montreal, Canada – December 8, 2020 – Theratechnologies …Lire la suite

Theratechnologies To Present At The Piper Sandler Virtual Healthcare Conference

Montreal, Canada – November 23, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1 and 2, 2020.

Theratechnologies Announces Data From Oral Presentation At AASLD Showing How Tesamorelin Can Reduce Fibrosis And NASH

Montreal, Canada – November 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of …Lire la suite

Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020

Montreal, Canada – November 6, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman, MD, …Lire la suite

Theratechnologies Announces Departure Of Chief Commercial Officer

Montreal, Canada – November 3, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Jovan Antunovic, Senior Vice President and Chief Commercial Officer, is leaving the Company to assume a new position. His resignation will be effective November 13, 2020. …Lire la suite

Theratechnologies To Present At Upcoming Investor Conferences On October 29 And November 10, 2020

Montreal, Canada – October 22, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences. Riley Securities Liver Disease Therapeutics Day Thursday, October 29, 2020 Panel discussion with Dr. Christian …Lire la suite